Press Releases
Jun 2, 2020
Summary ToggleIntellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the pricing of an underwritten public offering of
Jun 1, 2020
Summary ToggleIntellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that it has commenced an underwritten public
Jun 1, 2020
Summary ToggleRegeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities Regeneron gains rights to develop products for additional in vivo targets and new rights for ex vivo product development Intellia receives $100 million
May 12, 2020
Summary ToggleIntellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T cell engineering approaches Proprietary process supports NTLA-5001 and other potential therapies for
May 7, 2020
Summary ToggleIntellia Therapeutics Announces First Quarter 2020 Financial Results
On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020 On track to submit an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia, in 1H 2021
Apr 30, 2020
Summary ToggleIntellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl , M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience, and joins
Apr 30, 2020
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates
CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its first quarter 2020 financial results and operational
Apr 28, 2020
Summary ToggleIntellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Company to Present Three Oral and Two Poster Presentations on In Vivo and Engineered Cell Therapy Pipeline Programs CAMBRIDGE, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using
Mar 31, 2020
Summary ToggleFDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
CAMBRIDGE, Mass. , March 31, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced that the U.S.
Feb 27, 2020
Summary ToggleIntellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
On track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to dose first patients in 2H 2020 Plans to submit an IND application for NTLA-5001, a WT1-directed TCR-T cell therapy, for the treatment of acute myeloid leukemia in 1H 2021 Expects to